Business Wire

Mitsubishi Engineering-Plastics Has Developed a Medical Grade Polyacetal Resin, the "Iupital (TM) MA Series"

1.6.2021 03:00:00 CEST | Business Wire | Press Release

Share

Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.

The MA series is available in a range of standard, high-flow, high-rigidity, and low-friction grades, enabling greater design flexibility for medical devices and equipment, which are becoming smaller and lighter.

In particular, the low-friction grade MAL20 has greatly improved sliding performance with POM. In the past, combining POM parts would generate squeaking noise and friction, so designs would combine different materials in order to avoid these issues. MAL20 suppresses friction and wear, even when combined with ordinary POM, achieving quiet, smooth movement, which greatly improves comfort when used in medical devices.

In addition, with the MA series, we will offer a coloring masterbatch for color mixing. We support parts design not only in terms of physical characteristics, but also in terms of visual design.

MEP Vice President, Katsushige Hayashi, said the following. "These new materials, which exhibit a variety of excellent properties, will expand the range of designs, especially for medical devices and instruments, and contribute to improving their functionality. In particular, the sliding grade MAL20 eliminates the discomfort caused by noise and friction due to contact between POMs, providing users with comfort and ease of use."

The Iupital MA series meets the quality and regulatory requirements for medical materials, and is suitable for applications such as drug inhalers for COPD and asthma, injection devices such as insulin pens, and parts for medical devices.

Overview of Mitsubishi Engineering-Plastics Corporation

  1. Headquarters: Minato-ku, Tokyo
  2. Branches: Osaka Branch (Osaka, Osaka Prefecture), Nagoya Branch (Nagoya, Aichi Prefecture)
  3. Technical Base: Technical Center (Hiratsuka, Kanagawa Prefecture)
  4. President: Takashi Komaya
  5. Capital: 3 billion yen (50% invested by each of Mitsubishi Gas Chemical Company, Inc. and Mitsubishi Chemical Corporation)

Basic Information on the Iupital ™ MA Series

Features

  • We offer a variety of grade groups in addition to the standard grades, including high flow, high rigidity, and low friction
  • Masterbatch coloring available
  • Worldwide sales and technical support

Grade Lineup

  • MAS20 Standard: This is the grade with the most common physical properties and flowability
  • MAS30 High flow: This grade has increased flowability. Suitable for precision molding
  • MAH25 High rigidity: This grade has increased rigidity and strength. Suitable for making thinner walls and increasing strength
  • MAL20 Low-friction: This grade has excellent sliding characteristics. It contributes to low-noise designs with low sliding resistance

Supported Standards, Etc.

  • ISO10993-5, 10
  • USP [87]
  • USP [88] Class IV
  • FDA Drug Master File

For data on physical properties, etc., please download it from our website, or contact our sales staff at the nearest head office, branch office, or local subsidiary.

Basic Physical Properties Charts

https://www.m-ep.co.jp/ja/eve/18-2.html (Japanese)
https://www.m-ep.co.jp/en/eve/18-2.html (English)
https://www.m-ep.co.jp/ch/eve/18-2.html (Chinese)

Sales Bases

https://www.m-ep.co.jp/company/kaigai.html (Japanese)
https://www.m-ep.co.jp/en/company/kaigai.html (English)
https://www.m-ep.co.jp/ch/company/kaigai.html (Chinese)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact point for inquiries related to this matter:
Mitsubishi Engineering-Plastics Corporation
Representative: Shinya Hata
Sales Department, Business Division III Headquarters (tel. +81-3-6274-9190)
URL: https://www.m-ep.co.jp/en/

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press Release

The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen Chupka, executive vice president, National Association of Broadcasters. “This year’s Show reflects the accelerating pace of innovation and

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press Release

The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen Chupka, executive vice president, National Association of Broadcasters. “This year’s Show reflects the accelerating pace of innovation and

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press Release

The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products. “As the only company to have successfully secured and maintained MRTP authorizations for heated tobacco products in the U.S., we are confident that our science-based alternatives can help adult smokers transition away from combustible cigarettes,” said Stacey Kenned

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye